Orient Pharma and Generic Giant Cipla Ink Commercial Deal to Launch Third P4 Drug in the U.S.

Orient Pharma (OP) announced on March 1 the execution of a commercial agency agreement with Cipla/Invagen Pharmaceuticals, a top-10 global generic manufacturer. The deal grants Cipla exclusive rights to market OEP’s proprietary Tofacitinib XR (11mg/22mg), a long-acting oral extended-release generic, in the United States.